Abstract / Summary
Abstract Purpose To describe epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) receipt and overall survival (OS) in an Egyptian institutional cohort with EGFR-mutated metastatic non-small cell lung cancer. Methods We reanalysed a patient-level workbook for a retrospective cohort managed at Mansoura University between January 2016 and January 2024. Treatment receipt was described in 99 patients. OS was estimated from recorded durations and vital status using Kaplan–Meier methods. Progression and biomarker analyses were excluded because their source data could not be adequately reconciled. Results Seventy-three patients (73.7%) received a TKI, including 29 in the first line, 36 in the second line, and eight in later lines. Available drug records described gefitinib and erlotinib; one treated patient had unresolved drug coding. Retained study summaries attributed nonreceipt to poor performance status or deterioration in 14 patients, refusal in six, and access or reimbursement failure in six. OS was available for 94 patients, with 18 deaths. Estimated OS was 96.2% (95% confidence interval 88.7–98.8%) at 12 months and 74.2% (57.2–85.3%) at 24 months. Median follow-up was 18 months. All five patients with missing OS had received no TKI. Conclusion This selected cohort describes heterogeneous TKI receipt across treatment lines. Survival estimates are limited by heavy censoring and missing outcomes concentrated among untreated patients. These data support further study of treatment pathways but cannot establish treatment effects or population-level access rates.